Close Bookmark and Share This Page

Save to Browser Favorites / Bookmarks

Ask backflip blinklist BlogBookmark Bloglines BlogMarks Blogsvine BuddyMarks BUMPzee! CiteULike Connotea del.icio.us

Digg diigo DotNetKicks DropJack dzone Facebook Fark Faves Friendsite folkd.com Furl Google

Jamespot Jeqq Kaboodle kirtsy linkaGoGo LinkedIn Ma.gnolia Mister Wong Mixx MySpace Netvouz Newsvine

oneview OnlyWire PlugIM Propeller Reddit Segnalo Shoutwire Simpy Slashdot Surphace Sphinn Spurl

Squidoo StumbleUpon Technorati ThisNext Twitter Webride Windows Live Yahoo!

Email This to a Friend

  Link HTML: 

 Permalink: 

 If you like this then please subscribe to the RSS Feed.

Powered by Bookmarkify™

More »

(RTTNews) - Exelixis Inc. (EXEL: News ) reported interim data early Thursday morning, from the cohort of patients with metastatic castration-resistant prostate cancer, or CRPC, treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial.

Exelixis Inc. gapped up sharply Thursday and has continued to rise, with voulume at over a 4-month high. The stock is now up 1.28 at $6.00. Exelixis has broken out to a 6-month high and has also re-crossed its 200-day moving average.

Regards,

Don